Cargando…

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

BACKGROUND: The sensitivity of estrogen receptor-positive breast cancers to tamoxifen treatment varies considerably, and the molecular mechanisms affecting the response rates are manifold. The human epidermal growth factor receptor-related receptor HER2 is known to trigger intracellular signaling ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wege, Anja Kathrin, Chittka, Dominik, Buchholz, Stefan, Klinkhammer-Schalke, Monika, Diermeier-Daucher, Simone, Zeman, Florian, Ortmann, Olaf, Brockhoff, Gero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247692/ https://www.ncbi.nlm.nih.gov/pubmed/30458882 http://dx.doi.org/10.1186/s13058-018-1072-1

Ejemplares similares

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease
por: Brockhoff, Gero, et al.
Publicado: (2017)

Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer
por: Sassen, Andrea, et al.
Publicado: (2009)

A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2020)

CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2021)

Advanced Immune Cell Profiling by Multiparameter Flow Cytometry in Humanized Patient-Derived Tumor Mice
por: Bruss, Christina, et al.
Publicado: (2022)

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)
por: Wege, Anja K, et al.
Publicado: (2016)

Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology
por: Inwald, EC, et al.
Publicado: (2017)

Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice
por: Rom-Jurek, Eva-Maria, et al.
Publicado: (2018)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival
por: Inwald, Elisabeth Christine, et al.
Publicado: (2015)

Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients
por: Taubenhansl, Clara, et al.
Publicado: (2019)

Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
por: Inwald, E. C., et al.
Publicado: (2014)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2015)

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2013)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Auswirkungen der COVID-19-Pandemie auf die Inzidenz und Therapie von Krebserkrankungen
por: Inwald, Elisabeth C., et al.
Publicado: (2022)

Guideline concordant therapy improves survival in high-grade endometrial cancer patients
por: Scharl, Sophia, et al.
Publicado: (2022)

Long-term improvement of quality of life in patients with breast cancer: supporting patient-physician communication by an electronic tool for inpatient and outpatient care
por: Lindberg-Scharf, Patricia, et al.
Publicado: (2021)

Impact of cavity shaving on residual tumor rates in patients with primary invasive carcinoma and carcinoma in situ in breast conserving surgery
por: Fernández-Pacheco, Miriam, et al.
Publicado: (2022)

Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen
por: Ignatov, Atanas, et al.
Publicado: (2020)

Patients with Localised Prostate Cancer (T1 - T2) Show Improved Overall Long-Term Survival Compared to the Normal Population
por: Mathers, Michael J., et al.
Publicado: (2011)

Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells
por: Matevossian, Armine, et al.
Publicado: (2015)

Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer
por: Schüler-Toprak, Susanne, et al.
Publicado: (2023)

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
por: Lindberg, Karolina, et al.
Publicado: (2011)

Estrogen Actions in Triple-Negative Breast Cancer
por: Treeck, Oliver, et al.
Publicado: (2020)

Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma
por: Schulz, Daniela, et al.
Publicado: (2021)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125
por: Seitz, Stephan, et al.
Publicado: (2014)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
por: Hrstka, Roman, et al.
Publicado: (2013)

Polypoid endometriosis mimicking invasive cancer in an obese, postmenopausal tamoxifen user
por: Jaegle, William T., et al.
Publicado: (2017)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer
por: Treeck, Oliver, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c67nikgfis2b8s0ddqk4o17grd